RNAC

SEC source: 0002064832-26-000149 · form4.xml · derivative · entry 3

Hoge Elizabeth · CIK 0002000987 · 10% owner

Seven One Eight Three Four Irrevocable Trust · CIK 0002000959 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · as trustee

Disclosed balance after: 33,662.224

Underlying: Common Stock · 758,001 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On April 2, 2026, Seven One Eight Three Four Irrevocable Trust (the "Trust") elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.

F3 · price: On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023 (the "Merger"). These securities represent merger consideration payable as a result of the closing of the Merger and securities purchased in a private placement in November 2023.

F1 · derivative.exercise_date: On April 2, 2026, Seven One Eight Three Four Irrevocable Trust (the "Trust") elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.

F1 · derivative.expiration_date: On April 2, 2026, Seven One Eight Three Four Irrevocable Trust (the "Trust") elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.

F2 · ownership.nature: Shares are held by the Trust. The reporting person is a trustee of the Trust.

SEC source: 0002064832-26-000149 · form4.xml · nonDerivative · entry 1

Hoge Elizabeth · CIK 0002000987 · 10% owner

Seven One Eight Three Four Irrevocable Trust · CIK 0002000959 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · as trustee

Disclosed balance after: 5,313,261

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On April 2, 2026, Seven One Eight Three Four Irrevocable Trust (the "Trust") elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.

F2 · ownership.nature: Shares are held by the Trust. The reporting person is a trustee of the Trust.

SEC source: 0002064832-26-000148 · form4.xml · derivative · entry 3

Kalayoglu Murat · CIK 0002000002 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · by trust

Disclosed balance after: 33,662.224

Underlying: Common Stock · 758,001 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On April 2, 2026, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.

F3 · price: On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023 (the "Merger"). These securities represent merger consideration payable as a result of the closing of the Merger and securities purchased in a private placement in November 2023.

F1 · derivative.exercise_date: On April 2, 2026, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.

F1 · derivative.expiration_date: On April 2, 2026, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.

F2 · ownership.nature: Shares are held by the Trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the Trust.

SEC source: 0002064832-26-000148 · form4.xml · nonDerivative · entry 1

Kalayoglu Murat · CIK 0002000002 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · by trust

Disclosed balance after: 5,313,261

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On April 2, 2026, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.

F2 · ownership.nature: Shares are held by the Trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the Trust.

SEC source: 0001453687-26-000066 · wk-form4_1773432889.xml · nonDerivative · entry 1

Singer Michael · CIK 0002000122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,578

SEC source: 0001453687-26-000047 · wk-form4_1767907199.xml · nonDerivative · entry 1

Brunn Carsten · CIK 0001760229 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 323,530

F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

SEC source: 0001453687-26-000046 · wk-form4_1767907193.xml · nonDerivative · entry 1

Miljkovic Milos · CIK 0002000282 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,820

F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

SEC source: 0001453687-26-000045 · wk-form4_1767907186.xml · nonDerivative · entry 1

Davis Blaine · CIK 0001802188 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,220

F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

SEC source: 0001453687-26-000029 · wk-form4_1767734290.xml · derivative · entry 4

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2036-01-01

SEC source: 0001453687-26-000029 · wk-form4_1767734290.xml · nonDerivative · entry 1

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,646,285

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

SEC source: 0001453687-26-000035 · wk-form4_1767734336.xml · derivative · entry 2

ZENNER PATRICK J · CIK 0001139036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2036-01-01

SEC source: 0001453687-26-000035 · wk-form4_1767734336.xml · nonDerivative · entry 1

ZENNER PATRICK J · CIK 0001139036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,974

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

SEC source: 0001453687-26-000034 · wk-form4_1767734330.xml · derivative · entry 2

Seymour June Ann · CIK 0002093716 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2036-01-01

F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.

SEC source: 0001453687-26-000034 · wk-form4_1767734330.xml · nonDerivative · entry 1

Seymour June Ann · CIK 0002093716 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,500

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030.

SEC source: 0001453687-26-000031 · wk-form4_1767734302.xml · derivative · entry 2

English Emily · CIK 0002019791 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,000

Underlying: Common Stock · 71,000 shares

Expires 2036-01-01

F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.

SEC source: 0001453687-26-000031 · wk-form4_1767734302.xml · nonDerivative · entry 1

English Emily · CIK 0002019791 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,226

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030.

SEC source: 0001453687-26-000038 · wk-form4_1767734357.xml · derivative · entry 2

Brunn Carsten · CIK 0001760229 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 415,700

Underlying: Common Stock · 415,700 shares

Expires 2036-01-01

F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.

SEC source: 0001453687-26-000038 · wk-form4_1767734357.xml · nonDerivative · entry 1

Brunn Carsten · CIK 0001760229 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 347,296

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030.

SEC source: 0001453687-26-000039 · wk-form4_1767734365.xml · derivative · entry 2

DeSilva Nishan M · CIK 0001492386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2036-01-01

SEC source: 0001453687-26-000039 · wk-form4_1767734365.xml · nonDerivative · entry 1

DeSilva Nishan M · CIK 0001492386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,366

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

SEC source: 0001453687-26-000033 · wk-form4_1767734322.xml · derivative · entry 2

Davis Blaine · CIK 0001802188 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,000

Underlying: Common Stock · 109,000 shares

Expires 2036-01-01

F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.

SEC source: 0001453687-26-000033 · wk-form4_1767734322.xml · nonDerivative · entry 1

Davis Blaine · CIK 0001802188 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,811

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030.

SEC source: 0001453687-26-000037 · wk-form4_1767734348.xml · derivative · entry 2

Malik Kemal · CIK 0001797921 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2036-01-01

SEC source: 0001453687-26-000037 · wk-form4_1767734348.xml · nonDerivative · entry 1

Malik Kemal · CIK 0001797921 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,133

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

SEC source: 0001453687-26-000036 · wk-form4_1767734342.xml · derivative · entry 2

Miljkovic Milos · CIK 0002000282 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,000

Underlying: Common Stock · 77,000 shares

Expires 2036-01-01

F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.

SEC source: 0001453687-26-000036 · wk-form4_1767734342.xml · nonDerivative · entry 1

Miljkovic Milos · CIK 0002000282 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,393

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030.

SEC source: 0001453687-26-000032 · wk-form4_1767734312.xml · derivative · entry 2

BARABE TIMOTHY C · CIK 0001237409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2036-01-01

SEC source: 0001453687-26-000032 · wk-form4_1767734312.xml · nonDerivative · entry 1

BARABE TIMOTHY C · CIK 0001237409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,966

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

SEC source: 0001453687-26-000030 · wk-form4_1767734296.xml · derivative · entry 8

Singer Michael · CIK 0002000122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2036-01-01

SEC source: 0001453687-26-000030 · wk-form4_1767734296.xml · nonDerivative · entry 1

Singer Michael · CIK 0002000122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,133

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

SEC source: 0001453687-26-000028 · wk-form4_1767734285.xml · derivative · entry 3

Kalayoglu Murat · CIK 0002000002 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2036-01-01

SEC source: 0001453687-26-000028 · wk-form4_1767734285.xml · nonDerivative · entry 1

Kalayoglu Murat · CIK 0002000002 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 511,577

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

SEC source: 0001453687-26-000002 · wk-form4_1767387807.xml · derivative · entry 2

English Emily · CIK 0002019791 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,369

Underlying: Common Stock · 7,500 shares

Expires 2031-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On November 13, 2023, the issuer acquired the Delaware corporation which was then-known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the issuer's common stock in connection with the merger.

F1 · derivative.exercise_date: These options are currently fully vested and exercisable.

SEC source: 0001453687-26-000002 · wk-form4_1767387807.xml · nonDerivative · entry 1

English Emily · CIK 0002019791 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,226

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-25-000144 · wk-form4_1766095515.xml · derivative · entry 2

Bot Adrian Ion · CIK 0002101801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,200

Underlying: Common Stock · 17,200 shares

Expires 2035-12-15

F2 · derivative.exercise_date: This award will vest in 36 equal monthly installments, so that it shall be fully vested on December 16, 2028.

SEC source: 0001453687-25-000144 · wk-form4_1766095515.xml · nonDerivative · entry 1

Bot Adrian Ion · CIK 0002101801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,800

F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments following the date of grant so that the underlying shares will be fully vested on December 16, 2028.

SEC source: 0001453687-25-000132 · wk-form4_1765228029.xml · nonDerivative · entry 1

BARABE TIMOTHY C · CIK 0001237409 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,366

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.80 to $6.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-25-000130 · wk-form4_1764709364.xml · derivative · entry 2

English Emily · CIK 0002019791 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,869

Underlying: Common Stock · 7,500 shares

Expires 2031-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On November 13, 2023, the issuer acquired the Delaware corporation which was then-known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the issuer's common stock in connection with the merger.

F1 · derivative.exercise_date: These options are currently fully vested and exercisable.

SEC source: 0001453687-25-000130 · wk-form4_1764709364.xml · nonDerivative · entry 1

English Emily · CIK 0002019791 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,726

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-25-000127 · wk-form4_1763595344.xml · nonDerivative · entry 1

Singer Michael · CIK 0002000122 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,533

SEC source: 0001453687-25-000112 · wk-form4_1761681948.xml · derivative · entry 1

Seymour June Ann · CIK 0002093716 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-10-27

F1 · derivative.exercise_date: This option vests as to 25% on October 27, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on October 27, 2029.

SEC source: 0001453687-25-000089 · wk-form4_1747253745.xml · derivative · entry 2

English Emily · CIK 0002019791 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,369

Underlying: Common Stock · 7,500 shares

Expires 2031-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On November 13, 2023, the issuer acquired the Delaware corporation which was then-known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the issuer's common stock in connection with the merger.

F1 · derivative.exercise_date: These options are currently fully vested and exercisable.

SEC source: 0001453687-25-000089 · wk-form4_1747253745.xml · nonDerivative · entry 1

English Emily · CIK 0002019791 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,226

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-25-000068 · wk-form4_1744835744.xml · derivative · entry 2

English Emily · CIK 0002019791 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,869

Underlying: Common Stock · 7,500 shares

Expires 2031-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On November 13, 2023, the issuer acquired the Delaware corporation which was then-known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the issuer's common stock in connection with the merger.

F1 · derivative.exercise_date: These options are currently fully vested and exercisable.

SEC source: 0001453687-25-000068 · wk-form4_1744835744.xml · nonDerivative · entry 1

English Emily · CIK 0002019791 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,726

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 10

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 656,513

F5 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $10.395 to $11.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 9

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,643,685

F5 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $10.395 to $11.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 8

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 620,175

F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 7

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 616,724

F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.918 to $10.7461. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 6

SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,637,273